US stocks fell on Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his self-imposed ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Eli Lilly (LLY) stock hits a 52-week low as concerns over its weight-loss drug trial overshadow strong Q2 2025 results. Read ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults.  Based on the results, the ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares logged their biggest daily rise in over two weeks on Thursday, ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...